Clinical characteristics of the control subjects and patients with type 2 diabetes
| Control | Patients with type 2 diabetes | p Value | |
|---|---|---|---|
| No. (male/female) | 10 (3/7) | 30 (20/10) | – |
| Age (year) | 53.8±6.3 | 58.7±11.4 | 0.2094 |
| BMI (kg/m2) | 21.2±2.5 | 25.5±5.0 | 0.0105* |
| FPG (mg/dL) | 96.9±6.6 | 181.0±65.6 | 0.0003* |
| HbA1c (%) | 5.3±0.3 | 10.4±2.3 | <0.0001* |
| eGFR (ml/min/1.63 m2) | 80.3±15.4 | 78.0±17.9 | 0.699 |
| Diabetic therapy | |||
| S/M/G/P/S+M/A+S+M+A | 3/9/1/1/3/23 | – | |
| S+A+P/S+M+P/S+P | 2/2/1 | – | |
| G+P/N | 1/2 | – | |
| Antihypertensive drugs | |||
| Ar/C/Ar+ C/Ar+T/Ar+C+T/Ai | 4/4/4/1/2/1 | – | |
| Statins | 16 | – | |
All data (age, BMI, FPG, eGFR and HbA1c) in both groups followed the normal distribution confirmed by a χ2 goodness of fit test.
Data are expressed as mean±SD.
Statins refer to the number of the patients with statins-therapies.
*P<0.05 is defined as statistical significance.
Antihypertensive drugs refer to the number of the patients with respective antihypertensive drugs. Diabetic therapy refers to the number of the patients with respective diabetic therapies.
A, α glucosidase inhibitor; Ar, angiotensin-II receptor blocker (ARB); Ai, angiotensin converting enzyme inhibitor (ACE-I); BMI, body mass index; C, calcium channel blocker; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; G, glinides; HbA1c, hemoglobin A1c; M, metformin; N, no antidiabetic drugs; P, pioglitazone; S, sulfonylureas; T, thiazides.